Immunome (NASDAQ: IMNM) insider transactions
In the twelve months to 10 November 2026, executives and directors of Immunome reported 28 open-market sales of 1,228,648 shares ($27.5m) and 11 open-market purchases of 111,468 shares ($2.3m), by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 11 September 2026 | Higgins Jack | Chief Scientific Officer | Option exercise, 10b5-1 plan | +18,000 | $1.35 | 78,250 | Form 4 |
| 11 September 2026 | Higgins Jack | Chief Scientific Officer | Open-market sale, 10b5-1 plan | −13,200 | $25.32 | 65,050 | Form 4 |
| 11 September 2026 | Higgins Jack | Chief Scientific Officer | Gift, 10b5-1 plan | −8,800 | — | 56,250 | Form 4 |
| 12 August 2026 | Barchas Isaac | Director | Open-market sale, 10b5-1 plan | −11,048 | $27.25 | 92,211 | Form 4 |
| 11 August 2026 | Barchas Isaac | Director | Open-market sale, 10b5-1 plan | −62,291 | $26.23 | 0 | Form 4 |
| 10 August 2026 | Barchas Isaac | Director | Open-market sale, 10b5-1 plan | −10,125 | $26.07 | 62,291 | Form 4 |
| 7 August 2026 | Barchas Isaac | Director | Open-market sale, 10b5-1 plan | −15,248 | $26.06 | 72,416 | Form 4 |
| 6 August 2026 | Barchas Isaac | Director | Open-market sale, 10b5-1 plan | −20,840 | $26.06 | 87,664 | Form 4 |
| 4 August 2026 | Horn Kinney | Chief Business Officer | Option exercise, 10b5-1 plan | +50,366 | $12.92 | 50,366 | Form 4 |
| 4 August 2026 | Horn Kinney | Chief Business Officer | Option exercise, 10b5-1 plan | +40,250 | $10.60 | 90,616 | Form 4 |
| 4 August 2026 | Horn Kinney | Chief Business Officer | Open-market sale, 10b5-1 plan | −90,616 | $25.09 | 0 | Form 4 |
| 23 July 2026 | Siegall Clay B | President and CEO | Grant or award | +180,000 | — | 870,704 | Form 4 |
| 23 July 2026 | Stoneman Sandra G. | Chief Legal Officer & GC | Grant or award | +38,250 | — | 43,805 | Form 4 |
| 23 July 2026 | Horn Kinney | Chief Business Officer | Grant or award | +31,250 | — | 31,250 | Form 4 |
| 23 July 2026 | Higgins Jack | Chief Scientific Officer | Grant or award | +38,250 | — | 60,250 | Form 4 |
| 23 July 2026 | Rosett Max | Chief Financial Officer | Grant or award | +47,250 | — | 101,287 | Form 4 |
| 23 July 2026 | Lechleider Robert | Chief Medical Officer | Grant or award | +54,000 | — | 69,805 | Form 4 |
| 23 July 2026 | Tsai Philip | Chief Technical Officer | Grant or award | +38,250 | — | 81,550 | Form 4 |
| 7 July 2026 | Horn Kinney | Chief Business Officer | Option exercise, 10b5-1 plan | +1,092 | $12.92 | 1,092 | Form 4 |
| 7 July 2026 | Horn Kinney | Chief Business Officer | Open-market sale, 10b5-1 plan | −1,092 | $25.00 | 0 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Immunome page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.